One More Wrinkle in Battle for Botox Firm Allergan

Related Link: 

Allergan approached Salix Pharmaceuticals and at least one other company about a potential acquisition, as the Botox maker seeks to fend off a $53 billion hostile takeover from Valeant Pharmaceuticals.

Hospira Wins Delay Against FDA

Related Link: 

Hospira was granted a temporary restraining order against the FDA over the agency's approval of generic versions of the company's top-selling drug.

China Steps Up Antitrust Fight

Related Link: 

China levied a record $200 million combined fine against 10 Japanese auto-parts and bearings makers for antitrust activities, in its most dramatic move yet to tame prices in markets dominated by foreign companies.

Russia's Mobile TeleSystems Cuts Sales Forecast

Related Link: 

Russia's leading telecoms operator said it has cut its forecast for revenue growth, citing disruption to its business in Ukraine after months of conflict there.

JA Solar Profit Rises

Related Link: 

JA Solar Holdings said it swung to a profit in the second quarter as a surge in its solar energy equipment shipments drove revenue sharply higher.

Ballmer Steps Down From Microsoft Board

Related Link: 

Former Microsoft CEO Steve Ballmer quit his post as a company director after 14 years, giving new CEO Satya Nadella an even freer hand to reshape the company.

Home Depot's Profit, Outlook Rise

Related Link: 

Home Depot posted strong foot traffic and growth in sales of higher-end items in the most recent quarter, making it one of only a few retailers to raise its full-year profit forecast so far this quarter.

Canada Agency Issues Two Rail-Safety Recommendations

Related Link: 

Canada's transportation safety agency blamed a devastating oil-train derailment in Quebec last year on a host of factors and issued two new safety recommendations.

Marketing Decoder: Air-Powered Air Freshener

Related Link: 

Method Products' 'air care' product for environmentally conscious consumers

Broken Commitment Ruined Vascular Biogenics IPO

Related Link: 

Vascular Biogenics' shares had been trading for six days when its IPO was canceled and all those trades undone. The reason: A condition outlined in its prospectus wasn't met.

Syndicate content